George Clinical in China
China is George Clinical’s largest hub outside the head office of Sydney, offering full CRO services and a site network that spans the country.
With its immense potential for patient recruitment and a rapidly growing pharmaceutical market, China, currently the third largest in the world, is an obvious choice for many when entering the Asian market.
The Chinese healthcare delivery system consists of public hospitals and community healthcare centers, with an increasing private care system. Only GCP accredited sites are eligible for running commercial Phase I, II and III studies, and this accreditation can only be achieved by public hospitals in China. The accreditation is issued by the CFDA and NHPFC based upon a site inspection. Accreditation is renewed every 3 years, with a quality review performed by the PFDA every year.
George Clinical has an extensive network of over 260 trial centers in 50 cities for Phase II-IV trials, and a wider network that includes community health centers in semi-urban and rural areas for Phase IV trials.
What are the benefits of conducting clinical trials in China?
- China has access to a large patient pool
- Rapidly developing medical infrastructure in urban centres and centres of excellence for many common diseases such as hypertension, diabetes and renal disease
- Low operational costs
What are the prevalent diseases in China?
- Ischaemic Heart Disease
- Chronic obstructive pulmonary disease
- Road injury
- Diabetes mellitus
- Lower respiratory infections
George Clinical China News
The Australian state of New South Wales (NSW) and China explore opportunities to grow in health and medical research
710 Dongfang Road, Pudong District
|Number of Personnel:||50|
|Official Language:||Putonghua (Mandarin). Local dialects may be used|
|Hospital Records Language:||Simplified Chinese|
|Electronic Hospital Records:||Currently, paper records are used.|
|GDP – per capita (US $):||$14,100|
|Health expenditures:||5.6% of GDP|